Orchard Therapeutics

📍 London, United Kingdom🗓 Founded 2015👥 193 employees💰 Last funded Aug 2019
At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease in a single treatment. In 2018, the company acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Today, Orchard is advancing a pipeline spanning pre-clinical, clinical and commercial stage HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist. Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com,
3
Total investors
1
Early stage
2
Mid stage
0
Late stage
2015
Founded
Investor geography2 countries
United States
2
United Kingdom
1
Investor activity2016–2019 · investors recorded per year
201612018120191
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Orchard Therapeutics?
Orchard Therapeutics has 3 investors on record on gritt.io, including 1 early-stage backers, 2 mid-stage.
When did Orchard Therapeutics last raise funding?
The most recent investment in Orchard Therapeutics recorded on gritt.io was in August 2019.
When was Orchard Therapeutics founded?
Orchard Therapeutics was founded in 2015.
What industry is Orchard Therapeutics in?
Orchard Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Orchard Therapeutics based?
Orchard Therapeutics is headquartered in London, United Kingdom.